Modulation of the angiogenic phenotype of normal and systemic sclerosis endothelial cells by gain-loss of function of pentraxin 3 and matrix metalloproteinase 12

Arthritis and Rheumatism

Volumn 62, Issue 8, 2010, Pages 2488-2498

  Margheri, Francesca ^a   Serratì, Simona ^a   Lapucci, Andrea ^a   Chillà, Anastasia ^a   Bazzichi, Laura ^b   Bombardieri, Stefano ^b   Kahaleh, Bashar ^c   Calorini, Lido ^a   Bianchini, Francesca ^a   Fibbi, Gabriella ^a   Rosso, Mario Del ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2 ANTIBODY; MACROPHAGE ELASTASE; MATRIGEL; PENTRAXIN 3; PROTEIN ANTIBODY; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; ELECTROPORATION; ENDOTHELIUM CELL; FLUOROMETRY; GAIN OF FUNCTION MUTATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; MORPHOGENESIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; TRANSIENT TRANSFECTION; VASCULARIZATION; WESTERN BLOTTING;

BLOTTING, WESTERN; C-REACTIVE PROTEIN; CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; MATRIX METALLOPROTEINASE 12; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; SCLERODERMA, SYSTEMIC; SERUM AMYLOID P-COMPONENT; TRANSFECTION;

EID: 77955375536     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27522     Document Type: Article

References (32)

1. Wittekind C, Neid M. Cancer invasion and metastasis. Oncology 2005;69:14-6.
2. Carmeliet P, Collen D. Transgenic mouse models in angiogenesis and cardiovascular disease. J Pathol 2000;190:387-405. (Pubitemid 30141384)
3. Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 2000;11:617-24.
4. Maxwell PH. The HIF pathway in cancer. Semin Cell Dev Biol 2005;16:523-30.
5. Cutolo M, Grassi W, Matucci Cerinic M. Raynaud's phenomenon and the role of capillaroscopy [review]. Arthritis Rheum 2003;48:3023-30. (Pubitemid 37409311)
6. LeRoy EC. Systemic sclerosis: a vascular perspective. Rheum Dis Clin North Am 1996;22:675-94.
7. Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004;95:109-16.
8. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Defective vasculogenesis in systemic sclerosis. Lancet 2004;364:603-10.
9. D'Alessio S, Fibbi G, Cinelli M, Guiducci S, Del Rosso A, Margheri F, et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 2004;50:3275-85.
10. Margheri F, Manetti M, Serrati S, Nosi D, Pucci M, Matucci-Cerinic M, et al. Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, β2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum 2006;54:3926-38.
11. Giusti B, Fibbi G, Margheri F, Serrati S, Rossi L, Poggi F, et al. A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res Ther 2006;8:R115.
12. Presta M, Camozzi M, Salvatori G, Rusnati M. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med 2007;11:723-38. (Pubitemid 47313297)
13. Rusnati M, Camozzi M, Moroni E, Bottazzi B, Peri G, Indraccolo S, et al. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood 2004;104:92-9. (Pubitemid 38879843)
14. Giusti B, Serrati S, Margheri F, Papucci L, Rossi L, Poggi F, et al. The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. Arthritis Rheum 2005;52:3618-28.
15. Conrotto P, Valdembri D, Corso S, Serini G, Tamagnone L, Comoglio PM, et al. Sema4 induces angiogenesis through recruitment by plexin B1. Blood 2005;105:4321-9.
16. Suda K, Rothen-Rutishauser B, Gunthert M, Wunderli-Allenspach H. Phenotypic characterization of human umbilical vein endothelial (ECV304) and urinary carcinoma (T24) cells: endothelial versus epithelial features. In Vitro Cell Dev Biol Anim 2001;37:505-14. (Pubitemid 32973239)
17. Margheri F, D'Alessio S, Serrati S, Pucci M, Annunziato F, Cosmi L, et al. Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases. Gene Ther 2005;12:702-14.
18. Stathakis P, Fitzgerald M, Matthias LJ, Chesterman CN, Hogg PJ. Generation of angiostatin by reduction and proteolysis of plasmin. J Biol Chem 1997;272:29641-5.
19. Mandriota SJ, Pepper MS. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J Cell Sci 1997;110:2293-302.
20. Andolfo A, English WR, Resnati M, Murphy G, Blasi F, Sidenius N. Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor. Thromb Haemost 2002;88:298-306.
21. Gorrin-Rivas MJ, Arii S, Furutani S, Mizumoto M, Mori A, Hanaki K, et al. Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis. Clin Cancer Res 2000;6:1647-54.
22. Serrati S, Cinelli M, Margheri F, Guiducci S, Del Rosso A, Pucci M, et al. Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP-12-dependent cleavage of the endothelial cell urokinase receptor. J Pathol 2006;210:240-8.
23. Kugler MC, Wei Y, Chapman HA. Urokinase receptor and integrin interactions. Curr Pharm Des 2003;9:1565-74.
24. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 2007;97:336-42. (Pubitemid 46437793)
25. Madsen CD, Sidenius N. The interaction between urokinase receptor and vitronectin in cell adhesion and signalling. Eur J Cell Biol 2008;87:617-29.
26. Gately S, Twardowski P, Stack MS, Patrick M, Boggio L, Cundiff DL, et al. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res 1996;56:4887-90.
27. Stathakis P, Fitzgerald M, Matthias LJ, Chesterman CN, Hogg PJ. Generation of angiostatin by reduction and proteolysis of plasmin: catalysis by a plasmin reductase secreted by cultured cells. Biol Chem 1997;272:20641-5.
28. Stathakis P, Lay AJ, Fitzgerald M, Schlieker C, Matthias LJ, Hogg PJ. Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin. J Biol Chem 1999;274:8910-6.
29. Seghezzi G, Patel S, Ren CJ, Gualandris A, Pintucci G, Robbins ES, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 1998;141:1659-73.
30. Billottet C, Janji B, Thuery JP, Jouanneau J. Rapid tumor development and potent vescularization are independent events in carcinoma producing FGF-1 or FGF-2. Oncogene 2002;21:8128-39.
31. Mandriota SJ, Seghezzi G, Vassalli JD, Ferrara N, Wasi S, Mazzieri R, et al. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 1995;270:9709-16.
32. Dell'Era P, Belleri M, Stabile H, Massardi ML, Ribatti D, Presta M. Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells. Oncogene 2001;20:2655-63. (Pubitemid 32525296)